Revisiting Childhood-Onset Systemic Lupus Erythematosus


AVAR AYDIN P. Ö., Brunner H. I.

Turkish Archives of Pediatrics, cilt.59, sa.4, ss.336-344, 2024 (ESCI, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 59 Sayı: 4
  • Basım Tarihi: 2024
  • Doi Numarası: 10.5152/turkarchpediatr.2024.24097
  • Dergi Adı: Turkish Archives of Pediatrics
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.336-344
  • Anahtar Kelimeler: autoantibodies, childhood-onset, nephritis, neuropsychiatric, Systemic lupus erythematosus
  • Ankara Üniversitesi Adresli: Evet

Özet

Childhood-onset systemic lupus erythematosus (cSLE) is a chronic autoimmune disease with a multisystemic involvement diagnosed during childhood. The disease is marked by the production of autoantibodies targeting self-antigens, often before symptoms emerge. The presentation, clinical course, and outcome vary significantly among patients with cSLE. The onset of cSLE can be at any age during childhood while a diagnosis of cSLE before the age of 5 years is rare and raises a suspicion of monogenic lupus. Childhood-onset systemic lupus erythematosus affects various organs and systems, most frequently presenting with mucocutaneous, musculoskeletal, renal, and neuropsychiatric manifestations. Multiple disease flares can be seen during the disease course. Childhood-onset systemic lupus erythematosus causes significant morbidity and mortality. Children and adolescents with cSLE show higher disease activity and damage, and more aggressive immunosuppressive treatments are needed compared to adult-onset SLE. Early diagnosis can be difficult due to the insidious onset with nonspecific symptoms. Disease activity and damage measures aim to ensure an accurate evaluation of disease status. A multidisciplinary approach and individualized disease management are important. Disease management is complex including the control of disease activity, the reduction of flares and damage, and a limitation of drug toxicity while improving the health-related quality of life in patients with cSLE.